NCT06631157Recruiting
Essential Pro Study ( rEPIC04E-HK )
Essential Pro Post-Market Clinical Follow-up Study
Source: ClinicalTrials.gov · Last updated 17 Feb 2026
Brief summary (registry, in English)
Single center, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Essential Pro to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Essential Pro.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 2 Oct 2024
- Start date
- 15 May 2025
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Fundación EPIC
- Diseases
- Coronary artery disease
- NCT number
- NCT06631157
What you commit to
- Study type: Observational
- Planned participants: 100
- From 15 May 2025 to the primary completion date, 1 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Not meet inclusion criteria
Who the study is looking for
- Patient treated with Essential Pro according to routine hospital practice and following instructions for use
- Informed consent signed
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Princess Margaret Hospital Coordinator of this site? Confirm its status | Lai Chi Kok | Hong Kong | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.